Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (21-30 of 186) with videos related to

Pageof 19
Sort By:
Disease Models & Mechanisms|September 4, 2009
Translating the cancer genome into clinically useful tools and strategiesFederico Innocenti, Richard L Schilsky
Pharmacogenomics|February 9, 2010
Pharmacogenomics: paving the path to personalized medicineGeorge P Patrinos, Federico Innocenti
Cancer Informatics|February 7, 2015
Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping MicroarraysEric L Seiser, Federico Innocenti
Translational Oncology|December 1, 2020
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Gerard Milano, Federico Innocenti, Joseph Ciccolini
Cancer Science|April 21, 2022
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugsGérard Milano, Federico Innocenti, Hironobu Minami
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 14, 2012
The influence of UGT polymorphisms as biomarkers in solid organ transplantationRobert Dupuis, Andrea Yuen, Federico Innocenti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibilityWanqing Liu, Federico Innocenti, Mark J Ratain
Frontiers in Genetics|August 23, 2012
Liver expression quantitative trait loci: a foundation for pharmacogenomic researchDylan M Glubb, Neepa Dholakia, Federico Innocenti
Future Oncology (London, England)|April 9, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapyJacqueline Ramírez, Mark J Ratain, Federico Innocenti
Current Drug Targets|March 31, 2012
Systemic therapies for pancreatic cancer--the role of pharmacogeneticsRoss A Soo, Wei-Peng Yong, Federico Innocenti
Pageof 19

Showing results (21-30 of 186) with videos related to

Sort By:
Pageof 19
Disease Models & Mechanisms|September 4, 2009
Translating the cancer genome into clinically useful tools and strategiesFederico Innocenti, Richard L Schilsky
Pharmacogenomics|February 9, 2010
Pharmacogenomics: paving the path to personalized medicineGeorge P Patrinos, Federico Innocenti
Cancer Informatics|February 7, 2015
Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping MicroarraysEric L Seiser, Federico Innocenti
Translational Oncology|December 1, 2020
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Gerard Milano, Federico Innocenti, Joseph Ciccolini
Cancer Science|April 21, 2022
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugsGérard Milano, Federico Innocenti, Hironobu Minami
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 14, 2012
The influence of UGT polymorphisms as biomarkers in solid organ transplantationRobert Dupuis, Andrea Yuen, Federico Innocenti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibilityWanqing Liu, Federico Innocenti, Mark J Ratain
Frontiers in Genetics|August 23, 2012
Liver expression quantitative trait loci: a foundation for pharmacogenomic researchDylan M Glubb, Neepa Dholakia, Federico Innocenti
Future Oncology (London, England)|April 9, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapyJacqueline Ramírez, Mark J Ratain, Federico Innocenti
Current Drug Targets|March 31, 2012
Systemic therapies for pancreatic cancer--the role of pharmacogeneticsRoss A Soo, Wei-Peng Yong, Federico Innocenti
Pageof 19